{"filing":{"accession_number":"0001193125-26-256458","cik":"0001395937","ticker":"SNDX","company_name":"Syndax Pharmaceuticals Inc","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d65010d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/d65010d8k.htm"},"events":[{"id":6777,"run_id":5938,"accession_number":"0001193125-26-256458","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Syndax Pharmaceuticals entered into subscription agreements to issue $250 million of convertible senior notes due 2031 with conversion mechanics creating significant dilution potential to common shareholders. The unregistered private placement under Section 4(a)(2) will result in issuance of up to 13.6 million shares of common stock upon conversion, with net proceeds of approximately $243 million representing a material capital raise for the company.","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4297,"accession_number":"0001193125-26-256458","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Syndax entered into subscription agreements to issue $250 million of convertible senior notes due 2031 with a conversion price of approximately $24.76 per share (40.3894 shares per $1,000 principal). While technically a debt issuance, the convertible feature creates significant dilution potential to common shareholders, and the filing emphasizes the conversion mechanics and equity component. The net proceeds of ~$243 million represent a material capital raise for a pharmaceutical company, and convertible notes are typically classified as dilutive issuances due to their equity conversion feature.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4299,"accession_number":"0001193125-26-256458","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of convertible notes under Section 4(a)(2) of the Securities Act, with a maximum of 13,631,400 shares of Common Stock issuable upon conversion at a rate of 54.5256 shares per $1,000 principal amount. This is a classic dilutive issuance — a private placement of convertible securities that will result in substantial equity dilution to existing shareholders upon conversion.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4300,"accession_number":"0001193125-26-256458","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses pricing of \"the Notes\" on June 4, 2026, with a press release announcing the offering and its terms. While the Item 8.01 disclosure is sparse, the reference to \"pricing of the Notes\" and \"net proceeds from the Offering\" indicates a debt or convertible securities issuance. If these are convertible notes (a common capital-raising instrument), this would constitute a dilutive issuance material to investors assessing the company's capital structure and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6778,"run_id":5938,"accession_number":"0001193125-26-256458","anchor_item_number":"2.03","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Item 2.03 discloses creation of a direct financial obligation and incorporates Item 1.01 by reference, indicating a significant transaction creating material financial obligations consistent with M\u0026A activity or similar material transaction.","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4298,"accession_number":"0001193125-26-256458","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 discloses creation of a direct financial obligation and incorporates Item 1.01 by reference. Item 1.01 typically covers material acquisitions, dispositions, or changes of control. The cross-reference structure indicates a significant transaction creating financial obligations, most likely M\u0026A activity. Without the full Item 1.01 text, confidence is moderate but the materiality and structure strongly suggest acquisition or similar transaction activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4297,"accession_number":"0001193125-26-256458","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Syndax entered into subscription agreements to issue $250 million of convertible senior notes due 2031 with a conversion price of approximately $24.76 per share (40.3894 shares per $1,000 principal). While technically a debt issuance, the convertible feature creates significant dilution potential to common shareholders, and the filing emphasizes the conversion mechanics and equity component. The net proceeds of ~$243 million represent a material capital raise for a pharmaceutical company, and convertible notes are typically classified as dilutive issuances due to their equity conversion feature.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-04"},{"id":4298,"accession_number":"0001193125-26-256458","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 discloses creation of a direct financial obligation and incorporates Item 1.01 by reference. Item 1.01 typically covers material acquisitions, dispositions, or changes of control. The cross-reference structure indicates a significant transaction creating financial obligations, most likely M\u0026A activity. Without the full Item 1.01 text, confidence is moderate but the materiality and structure strongly suggest acquisition or similar transaction activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-04"},{"id":4299,"accession_number":"0001193125-26-256458","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of convertible notes under Section 4(a)(2) of the Securities Act, with a maximum of 13,631,400 shares of Common Stock issuable upon conversion at a rate of 54.5256 shares per $1,000 principal amount. This is a classic dilutive issuance — a private placement of convertible securities that will result in substantial equity dilution to existing shareholders upon conversion.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-04"},{"id":4300,"accession_number":"0001193125-26-256458","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses pricing of \"the Notes\" on June 4, 2026, with a press release announcing the offering and its terms. While the Item 8.01 disclosure is sparse, the reference to \"pricing of the Notes\" and \"net proceeds from the Offering\" indicates a debt or convertible securities issuance. If these are convertible notes (a common capital-raising instrument), this would constitute a dilutive issuance material to investors assessing the company's capital structure and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:55:17.706278+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-04"}]}